Business Wire

CGTN

17.9.2020 12:03:22 CEST | Business Wire | Press release

Share
CGTN: Xi Jinping Reviews Poverty Relief Progress in Hunan as China's War on Poverty Nears End

China has vowed to eradicate absolute poverty in rural areas by the end of 2020 despite the COVID-19 epidemic. While efforts are being made to ensure "no single poor area or individual shall be left behind" – as President Xi Jinping puts it – people that have recently shaken off poverty are striving for a better life.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005399/en/

Among the 529 residents in a small village in central China's Hunan Province, 95 in 30 households used to live under the poverty line. The whole village was lifted out of poverty through rural tourism in 2018, and the average annual income of the residents reached 13,840 yuan (about 2,060 U.S. dollars) last year – way above the national poverty line of 2,300 yuan (about 340 U.S. dollars).

Shazhou Village, located in a mountainous area in Rucheng County, Chenzhou City, was the first stop of Xi's inspection tour in Hunan.

Xi, also general secretary of the Communist Party of China (CPC) Central Committee, visited the village on Wednesday and learned about poverty relief industries and progress in consolidating poverty eradication at a modern agricultural tourism demonstration base.

Targeted poverty alleviation

China has adopted a targeted approach in its poverty alleviation campaign, which means taking tailored relief measures to fit different local conditions.

The story of Shazhou is a prime example of that approach. The village boasts the beautiful scenery of the Luoxiao Mountains and the unique Yao ethnic culture – nearly two thirds of the residents belong to the Yao ethnic group. Tourism has played a significant role in Shazhou's battle against poverty.

The village has promoted rural tourism and high-quality fruit planting, and arranged training programs to help villagers obtain such job skills as for restaurant cooks and rural tourism industry employees. More than 350 local jobs have been created through the efforts.

With all its residents lifted out of poverty, Shazhou has also been known for such national-level honor as the "village of beauty and leisure," "role model for ethnic unity and progress," "key village for promoting rural tourism" and "traditional Chinese village."

New starting point

Since the 18th CPC National Congress in late 2012, China has achieved remarkable results in poverty reduction. More than 93 million rural people shook off poverty between 2013 and 2019.

But 5.51 million people needed to get rid of poverty by the end of 2019. And such a formidable task was coincided by accident with the coronavirus outbreak.

Speaking at a symposium on poverty alleviation in March, Xi described the goal of ending absolute poverty by 2020 as a "solemn pledge" made by the CPC Central Committee to the Chinese people, urging authorities at all levels to deliver on that promise.

As China intensifies efforts in the final stage of the tough battle, Xi tours around the country to inspect economic and social development, with poverty alleviation high on the agenda. Prior to the Hunan trip, he had taken inspection tours this year of capital city Beijing and provinces of Yunnan, Hubei, Zhejiang, Shaanxi, Shanxi, Jilin and Anhui, and Ningxia Hui Autonomous Region.

In addition to increasing poor people's incomes, China is also striving to improve the quality of poverty relief. Xi has repeatedly called for efforts to ensure rural poor people do not have to worry about food and clothing and have access to compulsory education, basic medical services and safe housing.

Meanwhile, he is looking into the future beyond the end of poverty. "Being lifted out of poverty is not an end in itself but the starting point of a new life and a new pursuit," he said on several occasions this year, calling for consolidating achievements in poverty alleviation and advancing the rural vitalization strategy.

Put forward at the 19th CPC National Congress in 2017, the strategy aims to build rural areas with thriving businesses, pleasant living environments, social etiquette and civility, effective governance and prosperity.

Shazhou is among many previously poor villages in China that have embarked on the journey for a better future.

On Wednesday, Xi also visited a revolution-themed exhibition hall, a village service center, a clinic, a primary school and the homes of villagers in Shazhou.

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye